Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Parkinson's disease and the Stroop color word test: processing speed and interference algorithms.
Complement is activated in progressive multiple sclerosis cortical grey matter lesions.
Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap.
Integrated multidisciplinary clinics should be the gold standard in managing progressive MS - YES.
Drugs for multiple sclerosis.
Cutaneous and Mixed Nerve Silent Period Recordings in Symptomatic Paroxysmal Kinesigenic Dyskinesia.
Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the United States.
Recurrent myelopathy and optic neuritis associated with systemic lupus erythematosus.
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).
Normal-appearing brain tissue analysis in radiologically isolated syndrome using 3 T MRI.
Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine.
Diffusion tensor imaging predicts cognitive function change following partial brain radiotherapy for low-grade and benign tumors.
Regulation of PERK-eIF2α signalling by tuberous sclerosis complex-1 controls homoeostasis and survival of myelinating oligodendrocytes.
Longitudinal changes in sickness absence and disability pension, and associations between disability pension and disease-specific and contextual factors and functioning, in people with multiple sclerosis.
An attenuated immune response by Schwann cells and macrophages inhibits nerve regeneration in aged rats.
Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy.
Cognitive impairment among patients with multiple sclerosis: associations with employment and quality of life.
Gait Disturbance as the Presenting Symptom in Young Children With Anti-NMDA Receptor Encephalitis.
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS.
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system.
Interleukin 2 activates brain microvascular endothelial cells resulting in destabilization of adherens junctions.
[Immunity impact of pregnancy on the experience of the Obstetrics and Gynecology Department of Moulay Ismail Military Hospital].
Poster 463 Unexpected Transverse Myelitis after Dinutuximab Therapy for Relapsed Neuroblastoma: A Case Report.
Poster 353 Acute Onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) with CNS Involvement Initially Diagnosed as Guillain-Barre Syndrome (GBS): A Case Report.
Pages
« first
‹ previous
…
846
847
848
849
850
851
852
853
854
…
next ›
last »